The Fly

Altimmune initiated with a Buy at Goldman Sachs

Goldman Sachs analyst Corinne Jenkins initiated coverage of Altimmune with a Buy rating and $20 price target, which represents 101% upside potential. The analyst takes a positive view on the probability of a successful outcome for the Phase 2 MOMENTUM study of Altimmune’s lead asset, pemvidutide, in patients with obesity based on our assessment of the clinical data and a proprietary logistic growth model. A positive outcome from the trial provides proof-of-concept for pemvidutide in obesity, "unlocking a significant commercial opportunity for the agent where we also see a high degree of strategic interest," Jenkins tells investors in a research note.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on ALT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More